See a very important announcement fromaldconnect ALD Connect plans to submit a Letter of Interest to the FDA to host an Externally-Led Patient-Focused Drug Development meeting in April 2022. The primary goal of patient-focused drug development is to better incorporate the patient’s voice in drug development and evaluation. Our target population will be adults withContinue reading “FDA Patient-Focused Drug Development Meeting”